Loading
A phase 1/2 trial of Glumetinib in non-small-cell lung cancer, run by Haihe Biopharma Co., Ltd., now recruiting.
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04270591 by Haihe Biopharma Co., Ltd., with 183 participants planned, started 2019-07-15 and due to reach its primary completion in 2023-10-25. Interventions recorded: Glumetinib.
A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT04270591 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Glumetinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Haihe Biopharma and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.